Technology
Health
Biotechnology

AVROBIO

$15.77
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (0.06%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell AVROBIO and other stocks, options, ETFs, and crypto commission-free!

About

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. Read More These gene therapies, on which the company was founded, were developed by Dr. Jeffrey Medin and Dr. Christopher Paige at the University Health Network. AvroBio launched in 2015, is headed by Co-Founder, President and CEO Geoff Mackay, and is headquartered in Cambridge, MA.

Employees
49
Headquarters
Cambridge, Massachusetts
Founded
2015
Market Cap
377.76M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
161.30K
High Today
$16.64
Low Today
$15.43
Open Price
$15.54
Volume
72.72K
52 Week High
$53.70
52 Week Low
$11.85

Collections

Technology
Health
Biotechnology
Gene Therapies
Therapy
2018 IPO
US
North America

News

Yahoo FinanceMay 13

AVROBIO, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory clearances achieved that enable integration of the plato™ platform into Fabry FAB-201 and Gaucher GAU-201 clinical trials in the second half of 2019 IND for AVR-RD-01 for the treatment of Fabry disease cleared by the FDA; AVROBIO plans to open U.S. clinical trial sites for its ongoing multi-country FAB-201 trial Next interim Fabry clinical data update anticipated during summer 2019 Investigator-sponsored cystinosis clinical trial on track to start in the se...

46
Yahoo FinanceMay 12

Here’s What Hedge Funds Think About AVROBIO, Inc.

"Market volatility has picked up again over the past few weeks. Headlines highlight risks regarding interest rates, the Fed, China, house prices, auto sales, trade wars, and more. Uncertainty abounds. But doesn’t it always? I have no view on whether the recent volatility will continue for a while, or whether the market will be back at all-time highs before we know it. I remain focused on preserving and growing our capital, and continue to believe that the best way to do so is via a value-driven, concentrate...

24
Yahoo FinanceApr 29

AVROBIO, Inc. Announces FDA Clearance of Investigational New Drug Application for AVR-RD-01 Gene Therapy for the Treatment of Fabry Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- The plato™ platform represents a significant advance towards a commercial-stage gene therapy solution designed to treat thousands of patients AVROBIO to incorporate U.S. clinical sites into its ongoing global FAB-201 Phase 2 clinical trial in Fabry disease AVROBIO, Inc. (AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) applicati...

88

Earnings

-$2.98
-$2.15
-$1.32
-$0.49
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.72 per share
Actual
-$0.72 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.